These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Meijssen S; van Dijk H; Verseyden C; Erkelens DW; Cabezas MC Arterioscler Thromb Vasc Biol; 2002 May; 22(5):811-6. PubMed ID: 12006395 [TBL] [Abstract][Full Text] [Related]
9. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. Meijssen S; Cabezas MC; Twickler TB; Jansen H; Erkelens DW J Lipid Res; 2000 Jul; 41(7):1096-102. PubMed ID: 10884291 [TBL] [Abstract][Full Text] [Related]
10. Fatty liver is an integral feature of familial combined hyperlipidaemia: relationship with fat distribution and plasma lipids. Brouwers MC; Bilderbeek-Beckers MA; Georgieva AM; van der Kallen CJ; van Greevenbroek MM; de Bruin TW Clin Sci (Lond); 2007 Jan; 112(2):123-30. PubMed ID: 16958621 [TBL] [Abstract][Full Text] [Related]
11. [Disturbances of lipoprotein metabolism in metabolic syndrome]. Czyzewska M; Wolska A; Cwiklińska A; Kortas-Stempak B; Wróblewska M Postepy Hig Med Dosw (Online); 2010 Jan; 64():1-10. PubMed ID: 20093718 [TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Kwiterovich PO Am J Cardiol; 2002 Oct; 90(8A):30i-47i. PubMed ID: 12419479 [TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. Verseyden C; Meijssen S; van Dijk H; Jansen H; Castro Cabezas M J Lipid Res; 2003 Nov; 44(11):2100-8. PubMed ID: 12923226 [TBL] [Abstract][Full Text] [Related]
14. Atherogenic postprandial remnant lipoproteins; VLDL remnants as a causal factor in atherosclerosis. Nakajima K; Tanaka A Clin Chim Acta; 2018 Mar; 478():200-215. PubMed ID: 29307667 [TBL] [Abstract][Full Text] [Related]
16. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Oscarsson J; Hurt-Camejo E Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250 [TBL] [Abstract][Full Text] [Related]
17. Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia. Cruz-Bautista I; Mehta R; Cabiedes J; García-Ulloa C; Guillen-Pineda LE; Almeda-Valdés P; Cuevas-Ramos D; Aguilar-Salinas CA Clin Chim Acta; 2015 Jan; 438():160-5. PubMed ID: 25172037 [TBL] [Abstract][Full Text] [Related]
18. Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategies. Taghizadeh E; Esfehani RJ; Sahebkar A; Parizadeh SM; Rostami D; Mirinezhad M; Poursheikhani A; Mobarhan MG; Pasdar A IUBMB Life; 2019 Sep; 71(9):1221-1229. PubMed ID: 31271707 [TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states. Farr S; Taher J; Adeli K Cardiovasc Hematol Disord Drug Targets; 2014; 14(2):126-36. PubMed ID: 24801723 [TBL] [Abstract][Full Text] [Related]
20. Characterisation of the lipoprotein structure in the St. Thomas' Mixed Hyperlipidaemic (SMHL) rabbit. de Roos B; Caslake MJ; Milliner K; Benson GM; Suckling KE; Packard CJ Atherosclerosis; 2005 Jul; 181(1):63-8. PubMed ID: 15939055 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]